Swissmedic(Swissmedic)
Switzerland's regulatory authority for therapeutic products including medicines and medical devices.
Usage Examples
- The product received Swissmedic authorization via abridged procedure referencing the FDA approval.
- A Swiss Authorized Representative was appointed for EU MDR-certified devices entering the Swiss market.
What is Swissmedic?
Swissmedic is Switzerland's federal agency for authorization and supervision of therapeutic products. Switzerland is not an EU member, so Swissmedic operates independently of EMA while participating in international regulatory cooperation. Authorization can be obtained through standalone Swiss procedures, the Orphan Drug procedure, or abridged procedures recognizing approvals from the Access Consortium (FDA, Health Canada, MHRA, TGA, Swissmedic).
For medical devices, Switzerland recognizes EU CE marking for market access but requires a Swiss Authorized Representative (CH-REP) per Swiss Medical Device Ordinance. The Swiss-EU Mutual Recognition Agreement (MRA) on medical devices lapsed in May 2021, creating distinct Swiss regulatory pathways alongside EU MDR. Swiss marketing authorization holders must comply with Swiss-specific labeling and pharmacovigilance requirements.
Regulatory Context
This term appears most often in general workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside SWISS THERAPEUTIC PRODUCTS ACT, MEDICRIME CONVENTION.
When This Matters
- The product received Swissmedic authorization via abridged procedure referencing the FDA approval.
- A Swiss Authorized Representative was appointed for EU MDR-certified devices entering the Swiss market.
Common Mistakes
- Relying on generic terminology without mapping to the active jurisdiction context.
- Skipping cross-links between terms, tools, and active regulatory references.
- Failing to maintain a single source of truth for regulatory definitions internally.
Related Regulations
Frequently Asked Questions
Switzerland recognizes CE marking under MDR for market access but operates distinct national requirements including mandatory Swiss Authorized Representative. The MRA on medical devices lapsed in 2021, so Swiss-specific compliance applies alongside EU certification.
A coalition of FDA, Health Canada, MHRA, TGA, and Swissmedic that shares information and may conduct parallel reviews to enable faster access. Work-sharing reviews can expedite approval in participating jurisdictions.
Yes for medicinal products. Medicines cannot be marketed in Switzerland without Swissmedic authorization. For devices, CE marking with Swiss Authorized Representative enables market access without separate Swissmedic authorization.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track GxP regulation changes and enforcement trends
Related Regulatory Intelligence
Related Actions
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
510(k), De Novo, and PMA workflows from predicate analysis to filing.
Track every sequence operation, amendment, and supplement across the product lifecycle.
Sources & References
